Honey Bee Colony Collapse Disorder: New Suspects Have Been Identified

I previously blogged about honey bee colony collapse disorder (CCD) a disease that is destroying honey bee hives all over the world. While the incidence of the disease has been subsiding over the last year or so, it is still ravaging many hives. 

In the Wednesday edition of the online research journal PLOS a group of researchers from the University of Montana and the Army’s Edgewood Chemical Biological Center at Aberdeen Proving Grounds in Maryland suggested that CCD may be caused by two infectious agents; a virus and a fungus. 

Previously, many entomologists and apiary experts believed that CCD was possibly caused by multiple RNA viruses or the effect of certain pesticides. However, samples collected hives affected by CCD contained both a virus and a fungus whereas both agents were absent in unaffected hives. 

The new study said the suspect virus is insect iridescent virus (IIV) (Iridoviridae), which is similar to a virus first reported in India 20 years ago, as well as a virus found in moths. The virus infects the insect digestive system and the abdomen of infected insects takes on a bluish-green or purplish hue. The fungus, Nosema ceranae, can infect insects following ingested of its spores. Laboratory cage trials with a strain of IIV type 6 and Nosema ceranae confirmed that co-infection with these two pathogens was more lethal to bees than either pathogen alone.

Authors of the study speculate that initial infection of bee with one of the two agents makes infected bees more susceptible to infection by the second agent. In other words, primary infection by one agent followed by secondary infection may be responsible for the devastating effects of CCD. Further research will be necessary to confirm that both agents are responsible for CCD.

Until next time.....

Good Luck and Do Good Science!!!!!!

 

Public Library of Science Launches (PLOS) Launches a New Website for Rapid Research Communications

The Public Library of Science (PLOS) announced that it has launched a new website called PLOS Currents that is intended to serve as a vehicle for the rapid publication of scientific research and new ideas and themes. Not surprisingly, the first theme for PLOS Currents is influenza. On his Virology blog, Vincent Racaniello, a BioCrowd cofounder and prominent virologist, discusses why PLOS Currents is important and timely for scientist actively engaged in influenza research and vaccine development.  

The opening of PLoS Currents: Influenza was announced by Harold Varmus, Chairman and Co-Founder of PLoS. He wrote about the reasons for starting this website at The Official Google Blog:

The key goal of PLoS Currents is to accelerate scientific discovery by allowing researchers to share their latest findings and ideas immediately with the world’s scientific and medical communities. Google Knol’s features for community interaction, comment and discussion will enable commentary and conversations to develop around these findings. Given that the contributions to PLoS Currents are not peer-reviewed in detail, however, the results and conclusions must be regarded as preliminary. In time, it is therefore likely that PLoS Currents contributors will submit their work for publication in a formal journal, and the PLoS Journals will welcome these submissions.

Contributions that will be welcome at PLoS Currents: Influenza include research into influenza virology, genetics, immunity, structural biology, genomics, epidemiology, modeling, evolution, policy and control. The manuscripts will not be subject to peer-review, but unsuitable submissions will be screened out by a board of expert moderators. This policy will enable rapid publication of research.

The path to publishing original scientific research is often long and tortuous.  A manuscript describing the findings is prepared and submitted to a scientific journal (such as Nature, Cell, Journal of Virology). The manuscript is assigned to two or three expert reviewers, generally scientists involved in the same area of research. If their reviews are favorable, the paper is published. Usually additional experiments are called for, which may require additional time to complete. Many months to a year may pass before the paper is published, although some manuscripts (e.g. those on 2009 pandemic influenza) may be expedited. The point is that PLoS Currents: Influenza will allow everyone – including non-scientists – to read about research soon after the authors have prepared the paper.

PLoS Currents: Influenza is a terrific idea, and I welcome this venture with great enthusiasm. I hope that PLoS Currents will grow to include other areas of science. But Varmus warns:

Given that the contributions to PLoS Currents are not peer-reviewed in detail, however, the results and conclusions must be regarded as preliminary. In time, it is therefore likely that PLoS Currents contributors will submit their work for publication in a formal journal, and the PLoS Journals will welcome these submissions.

During peer review of submitted manuscripts, new experiments may be suggested that change some of the conclusions of the research. Hence, the papers that appear in PLoS Currents: Influenza may be different from final versions that are published elsewhere.

I wonder how other scientific journals will react to submissions of manuscripts that have appeared in PLoS Currents. Many journals do not accept manuscripts that have already appeared elsewhere. For example, the instructions to authors for the Journal of Virology state:

By submission of a manuscript to the journal, the authors guarantee that they have the authority to publish the work and that the manuscript, or one with substantially the same content, was not published previously, is not being considered or published elsewhere, and was not rejected on scientific grounds by another ASM journal.

It’s time for scientific journals to change this policy, and allow for preliminary publication at sites such as PLoS Currents.

Rapid and open-access publication will drive research forward and help inform and educate the public about science.

 SocialTwist Tell-a-Friend